The global Immune Thrombocytopenia (ITP) Market is predicted to touch USD 2,300 million at a 5.78% CAGR over the forecast period (2022-2030), as per the latest Market Research Future (MRFR) report. Immune thrombocytopenia (ITP), simply put, is a bleeding disorder which causes abnormal clotting. Severe fall in platelets counts, bleeding, and bruising are some of the discomforts caused by this disease. Typically, this is chronic in adults, yet is generally self-limited and acute in case of children. It is of two types- primary and secondary. The former happens on its own, and the latter is generally an offshoot of another condition. This condition can be triggered by specific type of cancers, during pregnancy, due to autoimmune disease and due to reactive medications.
The risk of immune thrombocytopenia is higher in people having antiphospholipid syndrome, lupus, and rheumatoid arthritis. Immune thrombocytopenia can result in small reddish-purple dots which appear as a rash or purple bruise. It may have no symptoms, but when it occurs it may include excessively heavy menstrual flow, blood in stools/urine, excessive or easy bruising, bleeding from nose or gums, and superficial bleeding in the skin which appear as reddish-purple spots that are pinpoint-sized and appear as a rash, generally on the lower legs.
Various factors are propelling the immune thrombocytopenia market growth. These factors, as stated by the MRFR report, include increasing prevalence of immune thrombocytopenia worldwide, rising government effort for improving healthcare infrastructure, and increased focus on novel drugs development and therapeutics.
The Market Research Future report provides a wide segmental analysis of the immune thrombocytopenia market based on treatment, type, and end user.
Based on end user, the immune thrombocytopenia market is segmented into research and academic institutes, hospitals and clinics, specialty centers, and others. Of these, the hospitals and clinic segment will have the largest share in the market over the forecast period. It is predicted to grow at a 6.22% CAGR.
Based on treatment, the immune thrombocytopenia market is segmented into intravenous immunoglobulins, corticosteroids, thrombopoietin receptor agonists, and others. Of these, the corticosteroids segment will dominate the market over the forecast period. It is predicted to grow at a 5.57% CAGR.
Based on type, the immune thrombocytopenia market is segmented into chronic immune thrombocytopenia and immune thrombocytopenia. Of these, the chronic immune thrombocytopenia segment will lead the market over the forecast period. This is owing to increasing prevalence of ITP and approval of various targeted treatments. It is predicted to touch USD 2,036.9 million at a 5.94% CAGR.
Based on the region, the immune Thrombocytopenia Market Report covers the latest trends and growth opportunities across the Americas, Europe, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, the Americas will dominate the market over the forecast period. This is owing to the increasing prevalence of ITP in Brazil, Mexico, Canada, and the US, favorable reimbursement policies, and high healthcare expenditure.
The immune thrombocytopenia market in Europe is predicted to have the second-largest share in the market over the forecast period. This is owing to strong government support and the presence of advanced and well-established healthcare infrastructure in the region.
The immune thrombocytopenia market in the APAC region is predicted to have a healthy growth over the forecast period. This is owing to the expanding patient pool, growing awareness, and rising penetration of healthcare services.
Leading players profiled in the immune thrombocytopenia market report include Novartis AG, CSL Limited, Shionogi Inc., F.Hoffmann-La Roche Ltd., Shire, Amgen Inc., Kyowa Hakko Kirin Co., Ltd., Rigel Pharmaceuticals, Inc., Ligand Pharmaceuticals, Inc., Jiangsu Hengrui Pharmaceutical Co., Ltd., and Dova Pharmaceuticals, among others.
July 2019: Dova Pharmaceutical, Inc. has announced the availability of DOPTELET for treating thrombocytopenia in adults suffering from chronic immune thrombocytopenia (ITP) having an insufficient response to earlier treatment. This medicine will integrate into the patient’s lifestyle easily and is the foremost oral thrombopoietin receptor agonist that is FDA-approved for treating patients sans food type restrictions.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071